chevron_left
EHA 2024
1. Managing the Unique Side Effects of Talquetamab | Ajai Chari, MD | EHA 2024 Video
bookmark_border
2. ASCO/EHA 2024 Myeloma Highlights | Ajai Chari, MD | EHA 2024 Video
bookmark_border
3. Phase I Study Findings: anitocabtagene autoleucel for RRMM treatment | Binod Dhakal, MD | EHA 2024 Video
bookmark_border
4. Phase 1b-2 Dose Escalation Study Sonrotoclax + Dexamethasone | Binod Dhakal, MD | EHA 2024 Video
bookmark_border
5. Real-World Schedule De-escalation of Teclistamab in Patients with RRMM | Carlyn Tan, MD | EHA 2024 Video
bookmark_border
6. ASCO/EHA Myeloma Updates 2024 | Claudio Cerchione, MD | EHA 2024 Video
bookmark_border
7. The Role of Combination FDG PET Plus Whole Body MRI for Staging | Claudio Cerchione, MD | EHA 2024 Video
bookmark_border
8. Cevostamab in RRMM Patients: CAMMA 2 Study Results | Joshua Richter, MD | EHA 2024 Video
bookmark_border
9. ASCO/EHA 2024 Myeloma Highlights - IMROZ, DREAMM-7, DREAMM-8 | Joshua Richter, MD | EHA 2024 Video
bookmark_border
10. CARTITUDE-4 Subgroup Analysis of Functional High-Risk Patients | Luciano Costa, MD | EHA 2024 Video
bookmark_border
11. Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 Trial | Luciano Costa, MD | EHA 2024 Video
bookmark_border
12. MAJESTIC-1 Study - A Subgroup Analysis of High-risk Patients | Luciano Costa, MD | EHA2024 Video
bookmark_border
13. DREAMM-7 Trial Update (BelaVd vs DaraVd) in RRMM | Maria Victoria Mateos, MD | EHA 2024 Video
bookmark_border
14. Frailty Adaptive Therapy in Newly Diagnosed Myeloma Patients | Maria Victoria Mateos, MD | EHA 2024 Video
bookmark_border
15. Bispecific Antibodies and Precision Medicine Insights on Myeloma Prognosis | Ola Landgren, MD | EHA 2024 Video
bookmark_border
16. Pereus Update D-VRd vs VRd Newly Diagnosed Transplant Eligible | Pieter Sonneveld, MD | EHA 2024 Video
bookmark_border
17. Integrating BCMA-Targeted Therapies into Challenging Myeloma Cases | Rakesh Popat, PhD | EHA 2024 Video
bookmark_borderadjust
18. Treating RRMM with Bispecific Antibodies | Rakesh Popat, PhD | EHA 2024 Video
bookmark_border
19. Real World Outcomes of RRMM Using Kyprolis | Sharlene Dong, MD, MS | EHA 2024 Video
bookmark_border
20. LINVOSELTAMAB in Patients with Relapsed/Refractory Myeloma | Suzanne Lentzsch MD, PhD | EHA 2024 Video
bookmark_border
21. IMROZ - IsaRVd vs RVd in Newly Diagnosed Transplant Ineligible MM | Thierry Facon, MD | EHA 2024 Video
bookmark_border
22. Ide-cel Without Front-Line ASCT: KARMMA-2 Cohort 2B | Xavier Leleu, MD, MSc, PhD, EHA 2024 Video
bookmark_border
23. Benefit Study IsaRVd vs IsaRd NDMM TI | Xavier Leleu, MD, MSc, PhD | EHA 2024 Video
bookmark_border
24. Elranatamab (ELEREXFIO) Trial Updates | Bryan Husbeck | EHA 2024 Video
bookmark_border![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}